In 2001 I was standing on a street corner in Melbourne, Australia. As I looked across the street, I saw Mel Mark. How could this be? Mel looked puzzled, even more than usual. He lookedone way, then the other, back and forth, and finally took off down the street before I could catch up. I have no idea whether he went in the right direction or even had a direction, but he did with greatenthusiasm. I thought, this is a man whose leadership I could follow. And here he is President of AEA. Amazing what enthusiastic misdirection will do. Of course, I am joking. I have great respect forMel\'s work. He and Gary Henry have made outstanding contributions to the field (though you have to wonder about their judgment in inviting a provocateur like me to give a speech ).
Blowback--Consequences of Evaluation for Evaluation
by Ernest R. House, , 28 October, 2006
Leading geneticist Samir Brahmachari explains why India should kickstart a new \'open source\' approach to drug discovery for diseases like TB.Samir Brahmachari is one of India\'s leading genetics researchers and the director general of India\'s Council of Scientific and Industrial Research (CSIR), a network of 38 government laboratories.rahmachari is kick-starting an \'open source\' approach to drug discovery, focusing first on tuberculosis (TB). He envisages a system where researchers all over the world work on different areas of drug design and deposit their findings into an open database for others to use and comment on — particularly for infectious diseases that affect the world\'s poor.As the world marks ten years since the genome of the TB-causing Mycobacterium tuberculosis was published — and with no new drugs on the immediate horizon — T. V. Padma talks to Brahmachari about the potential, and necessity, of open source drug discovery.
Q&A: Advocating open source drugs
by T.V.Padma, Science and Development Network, 12 June, 2008